This article's lead sectionmay be too short to adequately summarize the key points. Please consider expanding the lead to provide an accessible overview of all important aspects of the article.(July 2015)
This article needs to be divided into sections. Please help improve the article and read the Manual of Style for guidelines.(July 2015)
BMS-955176 is an experimental HIVmaturation inhibitor and is under development by Bristol-Myers Squibb for use in the treatment of HIV infection. By blocking the maturation of the virus, it prevents viral reproduction in host CD4+ T cells.[1] Because it targets a different step of the viral lifecycle, it offers promise for individuals with virus that has become highly resistant to other classes of HIV drugs.[2] Since this drug better handles naturally occurring changes in the Gag protease polyprotein, it is unlikely to promote resistance to itself unlike earlier maturation inhibitors.[3]